Table 2.
PESI for PE risk and diagnosis
|
First author, Year |
PESI |
Risk |
Diagnosis |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |
|
All-cause death |
PE-related death |
Adverse outcome |
All-cause death |
PE-related death |
Adverse outcome |
||||||
| PESI low risk | PESI high risk | PESI low risk | PESI high risk | PESI low risk | PESI high risk | Sensitivity | Specific | Sensitivity | Specific | Sensitivity | Specific | ||
| Lankeit M, 2011 |
sPESI |
1/198 (0.5%) |
26/328 (7.9%) |
0/198 (0.0%) |
8/328 (2.4%) |
2/198 (1.0%) |
29/328 (8.8%) |
0.963 |
0.395 |
1.000 |
0.382 |
0.935 |
0.396 |
| Sánchez D, 2011 |
sPESI |
7/407 (1.7%) |
120/884 (13.6%) |
2/407 (0.5%) |
58/884 (6.6%) |
Not mentioned |
Not mentioned |
0.945 |
0.344 |
0.967 |
0.329 |
N/A |
N/A |
| Lankeit M, 2012 |
sPESI |
0/165 (0.0%) |
40/361 (11.1%) |
Not mentioned |
Not mentioned |
3/165 (1.8%) |
18/361 (5.0%) |
1.000 |
0.340 |
N/A |
N/A |
0.857 |
0.321 |
| Righini M, 2011 |
sPESI |
1/165 (0.9%) |
10/192 (5.2%) |
1/165 (0.9%) |
6/192 (3.0%) |
Not mentioned |
Not mentioned |
0.909 |
0.474 |
0.857 |
0.469 |
N/A |
N/A |
| Spirk D, 2011 |
sPESI |
0/106 (0.0%) |
16/263 (6.1%) |
Not mentioned |
Not mentioned |
3/106 (2.9%) |
21/263 (8.0%) |
1.000 |
0.394 |
N/A |
N/A |
0.875 |
0.299 |
| Vanni S, 2011 |
PESI |
4/145 (2.8%) |
34/318 (10.7%) |
1/145 (0.7%) |
24/318 (7.5%) |
3/145 (2.1%) |
29/318 (9.1%) |
0.895 |
0.332 |
0.960 |
0.329 |
0.906 |
0.329 |
| Venetz C, 2011 |
PESI |
146/6332 (2.3%) |
1234/9179 (14.1%) |
Not mentioned |
Not mentioned |
63/6332 (1.0%) |
275/9179 (3.0%) |
0.894 |
0.438 |
N/A |
N/A |
0.814 |
0.417 |
| Venetz C, 2011 |
sPESI |
134/5715 (2.7%) |
1236/9816 (13.1%) |
Not mentioned |
Not mentioned |
69/5715 (1.2%) |
275/9816 (2.8%) |
0.902 |
0.394 |
N/A |
N/A |
0.799 |
0.372 |
| Hariharan P, 2011 |
PESI |
Not mentioned |
Not mentioned |
Not mentioned |
Not mentioned |
9/109 (8.3%) |
54/136 (39.7%) |
N/A |
N/A |
N/A |
N/A |
0.857 |
0.549 |
| Jiménez D, 2011 |
PESI |
Not mentioned |
Not mentioned |
1/199 (0.5%) |
36/392 (9.2%) |
Not mentioned |
Not mentioned |
N/A |
N/A |
0.973 |
0.357 |
N/A |
N/A |
| Singanayagam A, 2011 |
PESI |
1/197 (0.5%) |
22/214 (10.3%) |
Not mentioned |
Not mentioned |
Not mentioned |
Not mentioned |
0.957 |
0.505 |
N/A |
N/A |
N/A |
N/A |
| Jiménez D, 2010 (Derivation Cohort) |
PESI |
89/4235 (2.1%) |
857/6119 (14.0%) |
Not mentioned |
Not mentioned |
Not mentioned |
Not mentioned |
0.906 |
0.411 |
N/A |
N/A |
N/A |
N/A |
| Jiménez D, 2010 (Derivation Cohort) |
sPESI |
3/305 (1.0%) |
75/690 (10.9%) |
Not mentioned |
Not mentioned |
Not mentioned |
Not mentioned |
0.962 |
0.329 |
N/A |
N/A |
N/A |
N/A |
| Jiménez D, 2010 (RIETE Cohort) |
sPESI |
28/2565 (1.1%) |
404/4541 (8.9%) |
Not mentioned |
Not mentioned |
Not mentioned |
Not mentioned |
0.935 |
0.380 |
N/A |
N/A |
N/A |
N/A |
| Sam A, 2011 |
PESI |
16/431 (3.7%) |
103/775 (13.3%) |
Not mentioned |
Not mentioned |
Not mentioned |
Not mentioned |
0.866 |
0.382 |
N/A |
N/A |
N/A |
N/A |
| Sam A, 2011 |
sPESI |
6/369 (1.6%) |
113/837 (13.5%) |
Not mentioned |
Not mentioned |
8/369 (2.2%) |
34/837 (4.1%) |
0.950 |
0.334 |
N/A |
N/A |
0.810 |
0.310 |
| Chan CM, 2010 |
PESI |
0/106 (0.0%) |
9/196 (4.6%) |
Not mentioned |
Not mentioned |
Not mentioned |
Not mentioned |
1.000 |
0.362 |
N/A |
N/A |
N/A |
N/A |
| Singanayagam A, 2010 |
PESI |
6/288 (2.1%) |
38/297 (12.8%) |
Not mentioned |
Not mentioned |
Not mentioned |
Not mentioned |
0.864 |
0.521 |
N/A |
N/A |
N/A |
N/A |
| Moores L, 2010 |
PESI |
2/191 (1.0%) |
55/376 (14.6%) |
1/191 (1.5%) |
33/376 (8.8%) |
Not mentioned |
Not mentioned |
0.965 |
0.371 |
0.971 |
0.356 |
N/A |
N/A |
| Nordenholz K, 2011 |
PESI |
0/91 (0.0%) |
5/77 (6.5%) |
Not mentioned |
Not mentioned |
Not mentioned |
Not mentioned |
1.000 |
0.588 |
N/A |
N/A |
N/A |
N/A |
| Choi WH, 2009 |
PESI |
3/39 (7.7%) |
13/51 (25.5%) |
Not mentioned |
Not mentioned |
Not mentioned |
Not mentioned |
0.813 |
0.486 |
N/A |
N/A |
N/A |
N/A |
| Donzé J, 2008 |
PESI |
2/186 (1.1%) |
19/171 (11.1%) |
Not mentioned |
Not mentioned |
Not mentioned |
Not mentioned |
0.905 |
0.548 |
N/A |
N/A |
N/A |
N/A |
| Jiménez D, 2008 |
PESI |
0/100 (0.0%) |
12/218 (5.5%) |
Not mentioned |
Not mentioned |
Not mentioned |
Not mentioned |
1.000 |
0.327 |
N/A |
N/A |
N/A |
N/A |
| Jiménez D, 2007 (Validation Cohort) |
PESI |
2/216 (0.9%) |
41/383 (10.7%) |
Not mentioned |
Not mentioned |
6/216 (2.8%) |
26/383 (6.8%) |
0.953 |
0.385 |
N/A |
N/A |
0.813 |
0.370 |
| Aujesky D, 2007 | PESI | 5/426 (1.2%) | 53/573 (9.2%) | 3/426 (0.7%) | 18/573 (3.1%) | Not mentioned | Not mentioned | 0.914 | 0.447 | 0.857 | 0.433 | N/A | N/A |
Adverse outcome include nonfatal recurrent PE, nonfatal recurrent DVT, nonfatal bleeding, or delayed hemodynamic instability.